Journal Study: Liver Treatment Halves Alzheimer Protein in Aged Rats
Treating the liver with the experimental compound cinaciguat halved the levels of the Alzheimer-associated protein amyloid-beta in the blood of 24-month-old Fischer rats within two weeks, according to research published in the Journal of Biological Chemistry. The intervention re-opened microscopic pores in aging liver blood vessels that typically close over time, aligning the animals’ blood protein metrics with those of young control subjects.
Key Clinical Takeaways:
- Daily administration of cinaciguat for two weeks restored fenestrations in rat liver sinusoidal endothelial cells and reduced blood amyloid-beta-40 to youthful levels.
- The study points to an alternative clearance pathway bypassing the blood-brain barrier, using the liver to filter circulating blood proteins.
Restoring Liver Filtration to Lower Blood Amyloid-Beta
Alzheimer’s disease is widely studied as a pathology of the brain, yet nearly all direct brain therapeutics have faced severe clinical hurdles. A systematic evaluation published in the Journal of Alzheimer’s Disease documented only two successful approvals against 98 failed compounds across phase II and III trials between 2004 and 2022, yielding an approximate two percent success rate. Researchers attribute many of these failures to the blood-brain barrier, which obstructs the delivery of pharmacological agents to neural tissue.
Seeking an alternative route, a research team at the Keck School of Medicine of the University of Southern California investigated whether targeting a peripheral organ could clear neurotoxic peptides before deposition occurs. Young, healthy animals naturally clear roughly 60 percent of amyloid-beta introduced into the bloodstream. In humans, approximately 90 percent of circulating amyloid-beta-40 binds to lipoproteins, with the majority hitching to large lipid particles derived from nutrition and hepatic synthesis.
Cellular Changes in Hepatic Sinusoids
To ingest these large lipid particles, the liver relies on specialized microvascular structures known as sinusoidal endothelial cells. These cells are perforated by minute holes called fenestrae, which allow particles larger than 50 nanometers to reach underlying hepatocytes for degradation.
In the rodent study, untreated 24-month-old rats exhibited double the concentration of amyloid-beta-40 in their blood compared to four-month-old counterparts. Laurie DeLeve and colleagues administered daily doses of cinaciguat to a cohort of aged rats for two weeks. Cinaciguat functions by activating soluble guanylate cyclase, an enzyme responsible for synthesizing the messenger molecule cyclic GMP (cGMP). Untreated aged rats showed cGMP levels running 60 percent lower than young animals, a deficit fully corrected by the treatment.
Cellular Signaling and Lipid Reduction
Scanning electron microscopy confirmed that cinaciguat restored the fenestrations in the endothelial cells of the treated older rats, returning pore density to youthful parameters. Unexpectedly, the treatment also reduced levels of low-density lipoprotein (LDL) cholesterol and oxidized LDL, which are recognized vascular risk factors. Aged control rats harbored double the normal LDL and 2.8 times the oxidized LDL of young animals, figures that dropped significantly following the two-week intervention.
Further in vitro assays isolated the mechanism to a growth factor designated HB-EGF. Young endothelial cells secrete HB-EGF, whereas aged cells synthesize the factor but retain it intracellularly. Cinaciguat stimulated the release of HB-EGF, which in turn restored the surface expression of hepatic receptors LDLR and LRP1 responsible for binding and internalizing LDL and amyloid-beta.
Despite the reversal of vascular aging markers in rodents, several substantial barriers remain before human translation can be evaluated.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.